The Longevity Reality Radar
46 approaches, rated by evidence.

Rapamycin for longevity

Rapamycin (mTOR inhibition). Aging itself. Reviewed Jul 2026.

Extends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.

Stage
Approved drug, off-label use
Rung: Available now. Approved or established. Usable today, with a clinician.
Evidence grade
C
strong animal data
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

An existing immunosuppressant that extends lifespan across many species by dialing down the mTOR growth pathway.

The evidence

Strong animal data; human longevity benefit unproven. Bryan Johnson dropped it from his stack in 2026 over side effects (impaired wound healing, infection risk if misdosed).

What you can do today

This is available today. Whether it suits you depends on your health, your other medicines and your risks, so discuss it with a clinician who knows your history before starting or changing anything.

Sources

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Aging itself

All 17 in Aging itself.

  • Acarbose for longevityGrade C, strong animal data. Approved drug, off-label use.One of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
  • VO₂max and strength for longevityGrade B, large cohorts. Established.In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
  • RentosertibGrade C, post-hoc biomarker. Phase 3, for lung fibrosis.Six aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
  • Senolytics (dasatinib, quercetin, fisetin)Grade C, small human studies. Phase 1/2.Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
  • Partial epigenetic reprogramming (ER-100)Grade D, animal data only. Phase 1, in the eye.A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.
  • Therapeutic plasma exchange for agingGrade C, small trial, surrogate. Early clinical.A small trial lowered biological-age scores by about 1.3 years, a surrogate marker, and there is no outcome data.

Guides that cover this